Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
582 Views
Climate Action - School Strikes Hit a Spot, Carbon Emitters Face Heat. Investors Take Note
On Friday, March 15th, an estimated 1.6 million students in over 120 countries (source: Time magazine) walked out of classrooms and took to streets...
657 Views
Biosimilar Battlefield: The Remsima/Inflectra Warning
2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...
678 Views
Amarin--2019's Biggest Buyout Target for Big Pharma
Amarin (AMRN US), a US-listed biotech firm, presented the full results of its "Reduce-It" (RI) clinical trial at a conference for the American...
4.7k Views
J&J Tenders for Ci:z Holdings
Today after the close, Johnson & Johnson (JNJ US)announced a US$2bn+ deal and Tender Offer to buy the 52% of Ci:z Holdings (4924 JP) not held...
571 Views